Patents by Inventor John C. Bell
John C. Bell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240132913Abstract: The disclosure relates to modified orthopoxvirus vectors, as well as methods of using the same for the treatment of various cancers. The disclosure provides modified orthopoxvirus vectors that exhibit various beneficial therapeutic activities, including enhanced oncolytic activity, spread of infection, immune evasion, tumor persistence, capacity for incorporation of exogenous DNA sequences and safety. The viruses we have discovered are also amenable to large scale manufacturing protocols.Type: ApplicationFiled: September 4, 2023Publication date: April 25, 2024Applicants: OTTAWA HOSPITAL RESEARCH INSTITUTE, TURNSTONE BIOLOGICS CORP.Inventors: John C. Bell, Fabrice Le Boeuf, Michael S. Huh, Matthew Y. Tang, Adrian Pelin, Brian Andrew Keller, Caroline J. Breitbach, Michael F. Burgess, Steven H. Bernstein
-
Patent number: 11802292Abstract: The disclosure relates to modified orthopoxvirus vectors, as well as methods of using the same for the treatment of various cancers. The disclosure provides modified orthopoxvirus vectors that exhibit various beneficial therapeutic activities, including enhanced oncolytic activity, spread of infection, immune evasion, tumor persistence, capacity for incorporation of exogenous DNA sequences and safety. The viruses we have discovered are also amenable to large scale manufacturing protocols.Type: GrantFiled: January 4, 2019Date of Patent: October 31, 2023Assignees: OTTAWA HOSPITAL RESEARCH INSTITUTE, TURNSTONE BIOLOGICS CORP.Inventors: John C. Bell, Fabrice Le Boeuf, Michael S. Huh, Matthew Y. Tang, Adrian Pelin, Brian Andrew Keller, Caroline J. Breitbach, Michael F. Burgess, Steven H. Bernstein
-
Publication number: 20230022757Abstract: The disclosure relates to modified vaccinia virus vectors derived from the Copenhagen strain of vaccinia virus, as well as methods of using the same for the treatment of various cancers. The disclosure provides modified Copenhagen-derived vaccinia virus vectors that exhibit various beneficial therapeutic activities, including enhanced oncolytic activity, spread of infection, immune evasion, tumor persistence, capacity for incorporation of exogenous DNA sequences, amenability for large scale manufacturing, and safety.Type: ApplicationFiled: March 14, 2022Publication date: January 26, 2023Applicant: OTTAWA HOSPITAL RESEARCH INSTITUTEInventors: John C. Bell, Fabrice Le Boeuf, Michael S. Huh, Matthew Y. Tang, Brian Andrew Keller, Adrian Pelin
-
Publication number: 20220380799Abstract: The disclosure relates to modified orthopoxvirus vectors, as well as methods of using the same for the treatment of various cancers. The disclosure provides modified orthopoxvirus vectors that exhibit various beneficial therapeutic activities, including enhanced oncolytic activity, spread of infection, immune evasion, tumor persistence, capacity for incorporation of exogenous DNA sequences, amenability for large scale manufacturing, and safety.Type: ApplicationFiled: December 20, 2019Publication date: December 1, 2022Applicants: OTTAWA HOSPITAL RESEARCH INSTITUTE, TURNSTONE BIOLOGICS CORP.Inventors: John C. BELL, Michael S. HUH, Matthew Y. TANG, Adrian PELIN, Caroline J. BREITBACH, Michael F. BURGESS, Steven H. BERNSTEIN
-
Publication number: 20220056480Abstract: The disclosure relates to modified orthopoxvirus vectors, as well as methods of using the same for the treatment of various cancers. The disclosure provides modified orthopoxvirus vectors that exhibit various beneficial therapeutic activities, including enhanced oncolytic activity, spread of infection, immune evasion, tumor persistence, capacity for incorporation of exogenous DNA sequences, amenability for large scale manufacturing, and safety.Type: ApplicationFiled: December 20, 2019Publication date: February 24, 2022Applicants: OTTAWA HOSPITAL RESEARCH INSTITUTE, TURNSTONE BIOLOGICS CORP.Inventors: John C. BELL, Michael S. HUH, Matthew Y. TANG, Adrian PELIN, Caroline J. BREITBACH, Michael F. BURGESS, Steven H. BERNSTEIN
-
Publication number: 20200392535Abstract: The disclosure relates to modified orthopoxvirus vectors, as well as methods of using the same for the treatment of various cancers. The disclosure provides modified orthopoxvirus vectors that exhibit various beneficial therapeutic activities, including enhanced oncolytic activity, spread of infection, immune evasion, tumor persistence, capacity for incorporation of exogenous DNA sequences and safety. The viruses we have discovered are also amenable to large scale manufacturing protocols.Type: ApplicationFiled: January 4, 2019Publication date: December 17, 2020Applicants: OTTAWA HOSPITAL RESEARCH INSTITUTE, TURNSTONE BIOLOGICS CORP.Inventors: John C. BELL, Fabrice LE BOEUF, Michael S. HUH, Matthew Y. TANG, Adrian PELIN, Brian Andrew KELLER, Caroline J. BREITBACH, Michael F. BURGESS, Steven H. BERNSTEIN
-
Publication number: 20200385758Abstract: The disclosure relates to modified vaccinia virus vectors derived from the Copenhagen strain of vaccinia virus, as well as methods of using the same for the treatment of various cancers. The disclosure provides modified Copenhagen-derived vaccinia virus vectors that exhibit various beneficial therapeutic activities, including enhanced oncolytic activity, spread of infection, immune evasion, tumor persistence, capacity for incorporation of exogenous DNA sequences, amenability for large scale manufacturing, and safety.Type: ApplicationFiled: January 4, 2019Publication date: December 10, 2020Applicant: OTTAWA HOSPITAL RESEARCH INSTITUTEInventors: John C. BELL, Fabrice LE BOEUF, Michael S. HUH, Matthew Y. TANG, Brian Andrew KELLER, Adrian PELIN
-
Patent number: 10603351Abstract: In one aspect, the invention provides methods for preferentially killing target proliferating cells in a host, such as cancer cells, by infecting host tissues with two or more strains of virus. The strains of virus may be selected to provide a synergistic and symbiotic effect, involving a contemporaneous lytic infection in the target proliferating cells. In selected embodiments, the viruses are selected so that expression of a first virulence factor in proliferating cells infected with the first virus increases the lytic effect of the second virus; and, expression of the second virulence factor in proliferating cells infected with the second virus increases the lytic effect of the first virus. The genomes of the first and second viruses may be selected so that they are incompatible for recombination between the viral genomes in cells of the host.Type: GrantFiled: August 20, 2009Date of Patent: March 31, 2020Assignee: TURNSTONE LIMITED PARTNERSHIPInventors: John C. Bell, Fabrice Le Boeuf
-
Publication number: 20180305345Abstract: Provided are compounds that enhance the efficacy of viruses by increasing spread of the virus in cells, increasing the titer of virus in cells, or increasing the cytotoxicity of virus to cells. Other uses, compositions and methods of using same are also provided.Type: ApplicationFiled: January 26, 2016Publication date: October 25, 2018Applicants: Ottawa Hospital Research Institute, University of OttawaInventors: Jean-Simon Diallo, Christopher Noyce Boddy, Mark Dornan, Ramya Krishnan, Fabrice Le Boeuf, John C. Bell, Andrew Macklin, Jeffrey Smith
-
Patent number: 9896664Abstract: Embodiments of the invention include compositions and methods related to Maraba virus and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo.Type: GrantFiled: April 24, 2015Date of Patent: February 20, 2018Assignee: Turnstone Limited PartnershipInventors: John C. Bell, David F. Stojdl
-
Publication number: 20150275185Abstract: Embodiments of the invention include compositions and methods related to Maraba virus and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo.Type: ApplicationFiled: April 24, 2015Publication date: October 1, 2015Inventors: John C. BELL, David F. STOJDL
-
Patent number: 9045729Abstract: Embodiments of the invention include compositions and methods related to Maraba virus and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo.Type: GrantFiled: December 10, 2010Date of Patent: June 2, 2015Assignees: Ottawa Hospital Research Institute, Children's Hospital of Eastern Ontario Research Institute Inc.Inventors: John C. Bell, David F. Stojdl
-
Publication number: 20140052480Abstract: An insurance claim report generating system includes an interactive voice response (IVR) system, a voice recognition server, and a voice activated database (VAD) device. The IVR system receives telephone calls from remote devices, delivers audio scripts having prompts directed by both templates and data received from the remote devices. The IVR system receives dual-tone, multi-frequency (DTMF) information and human voice information in response to the prompts. The voice recognition server generates text from the human voice information using a dictionary of insurance relevant terms. The VAD device receives first digital information from the IVR system and second digital information from the voice recognition server. The first digital information is derived from the DTMF information, and the second digital information is derived from the human voice information. The VAD device generates an insurance claim report from at least some of the first or second digital information.Type: ApplicationFiled: August 16, 2013Publication date: February 20, 2014Applicant: Pilot Catastrophe Services, Inc.Inventors: John C. Bell, Colm M. Keenan
-
Publication number: 20120275999Abstract: Embodiments of the invention include compositions and methods related to Maraba virus and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo.Type: ApplicationFiled: December 10, 2010Publication date: November 1, 2012Applicants: CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC., OTTAWA HOSPITAL RESEARCH INSTITUTEInventors: John C. Bell, David F. Stojdl
-
Patent number: 8282917Abstract: The present invention provides mutant viruses with a decreased ability to block nuclear transport of mRNA or protein in an infected cell which are attenuated in vivo. The mutant viruses of the present invention may also be capable of triggering the anti-viral systems of normal host cells while remaining sensitive to the effects of these systems. The present invention further provides for the use of the mutant viruses in a range of applications including, but not limited to, as therapeutics for the treatment of cancer and infections, as vaccines and adjuvants, as viral vectors, and as oncolytic and cytolytic agents for the selective lysis of malignant or infected cells.Type: GrantFiled: March 30, 2010Date of Patent: October 9, 2012Assignees: Wellstat Biologics Corporation, Ottawa Hospital Research InstituteInventors: John C. Bell, Brian D. Lichty, David F. Stodjl
-
Patent number: 8227440Abstract: The present invention relates to therapeutic use of Myxoma virus. Myxomas virus can selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon and can be used to treat diseases characterized by the presence of such cells, including cancer.Type: GrantFiled: August 28, 2009Date of Patent: July 24, 2012Assignee: Robarts Research InstituteInventors: Grant McFadden, John C. Bell
-
Patent number: 8147822Abstract: The present invention is directed to a method of reducing the viability of a tumor cell involving administering a virus that is not a common human pathogen to the tumor cell. Preferably, the virus exhibits differential susceptibility, in that normal cells are not affected by the virus. This differential susceptibility is more pronounced in the presence of interferon. The tumor cell is characterized by having low levels, or no, PKR activity, or as being PKR?/?, STAT1?/? or both PKR?/? and STAT1?/?. The virus is selected from the group consisting of Rhabdovirus and picornavirus, and preferably is vesicular stomatitis virus (VSV) or a derivative thereof.Type: GrantFiled: September 18, 2000Date of Patent: April 3, 2012Assignee: Wellstat Biologics CorporationInventors: John C. Bell, Nahum Sonenberg, David F. Stojdl, Earl G. Brown, Harold L. Atkins, Ricardo M. Marius, Brian D. Lichty, Shane B. Knowles
-
Publication number: 20110206640Abstract: In one aspect, the invention provides methods for preferentially killing target proliferating cells in a host, such as cancer cells, by infecting host tissues with two or more strains of virus. The strains of virus may be selected to provide a synergistic and symbiotic effect, involving a contemporaneous lytic infection in the target proliferating cells. In selected embodiments, the viruses are selected so that expression of a first virulence factor in proliferating cells infected with the first virus increases the lytic effect of the second virus; and, expression of the second virulence factor in proliferating cells infected with the second virus increases the lytic effect of the first virus. The genomes of the first and second viruses may be selected so that they are incompatible for recombination between the viral genomes in cells of the host.Type: ApplicationFiled: August 20, 2009Publication date: August 25, 2011Applicant: OTTAWA HOSPITAL RESEARCH INSTITUTEInventors: John C. Bell, Fabrice Le Boeuf
-
Publication number: 20110044937Abstract: The invention provides methods for treating tumours, such as solid tumours, in a host. The methods may involve infecting the tumour with an amount of one or more strains of oncolytic virus. The virus will generally be selected to be effective to cause a lytic infection of tumour cells within the tumour. In various embodiments, the host neutrophil response to the lytic infection may be modulated, so that during the course of the lytic infection, the host has an initial neutrophil response and a secondary neutrophil response, these two responses being different in some material respect. For example, the secondary neutrophil response may mediate a greater degree of apoptotic killing of tumour cells than does the initial neutrophil response.Type: ApplicationFiled: July 27, 2007Publication date: February 24, 2011Applicant: OTTAWA HEALTH RESEARCH INSTITUTEInventors: John C. Bell, Caroline Judith Breitbach, Harry Atkins
-
Publication number: 20100272687Abstract: The present invention provides mutant viruses with a decreased ability to block nuclear transport of mRNA or protein in an infected cell which are attenuated in vivo. The mutant viruses of the present invention may also be capable of triggering the anti-viral systems of normal host cells while remaining sensitive to the effects of these systems. The present invention further provides for the use of the mutant viruses in a range of applications including, but not limited to, as therapeutics for the treatment of cancer and infections, as vaccines and adjuvants, as viral vectors, and as oncolytic and cytolytic agents for the selective lysis of malignant or infected cells.Type: ApplicationFiled: March 30, 2010Publication date: October 28, 2010Inventors: John C. Bell, Brian D. Lichty, David F. Stojdl